← All trials
NCT04670679
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2020
- Primary completion
- May 31, 2024
- Completion date
- May 31, 2024
- First posted
- Dec 17, 2020
- Last posted
- Dec 19, 2020
- Enrollment
- 170
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Erasca, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.